Your browser is no longer supported. Please, upgrade your browser.
Anika Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own0.10% Shs Outstand14.43M Perf Week-4.16%
Market Cap480.38M Forward P/E90.31 EPS next Y0.36 Insider Trans32.17% Shs Float14.28M Perf Month-15.14%
Income-5.70M PEG- EPS next Q-0.26 Inst Own93.10% Short Float6.85% Perf Quarter-24.37%
Sales144.70M P/S3.32 EPS this Y-189.10% Inst Trans-0.17% Short Ratio10.74 Perf Half Y-21.63%
Book/sh20.10 P/B1.60 EPS next Y-10.08% ROA-1.60% Target Price50.75 Perf Year-15.60%
Cash/sh- P/C- EPS next 5Y10.00% ROE-2.00% 52W Range31.20 - 48.37 Perf YTD-10.02%
Dividend- P/FCF240.19 EPS past 5Y-23.20% ROI-8.70% 52W High-33.14% Beta1.13
Dividend %- Quick Ratio4.50 Sales past 5Y7.00% Gross Margin56.40% 52W Low3.65% ATR1.35
Employees277 Current Ratio5.80 Sales Q/Q24.60% Oper. Margin-4.30% RSI (14)31.50 Volatility4.30% 3.39%
OptionableYes Debt/Eq0.00 EPS Q/Q108.40% Profit Margin-4.00% Rel Volume0.22 Prev Close32.24
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume91.10K Price32.34
Recom1.50 SMA20-6.59% SMA50-13.09% SMA200-20.59% Volume8,889 Change0.31%
Nov-16-21Initiated Stephens Overweight $55
Jul-16-21Initiated UBS Neutral $46
Dec-16-20Upgrade Barrington Research Mkt Perform → Outperform $43
May-08-20Downgrade Barrington Research Outperform → Mkt Perform
Jan-21-20Upgrade Sidoti Neutral → Buy $61
Jan-10-20Upgrade First Analysis Sec Outperform → Strong Buy $65
Nov-05-19Initiated BWS Financial Sell $29
Sep-24-19Reiterated Barrington Research Outperform $49 → $58
Sep-23-19Downgrade First Analysis Sec Strong Buy → Outperform $54
Jul-25-19Upgrade First Analysis Sec Neutral → Strong Buy $37 → $54
Feb-22-19Downgrade Sidoti Buy → Neutral $56 → $41
Feb-22-19Downgrade First Analysis Sec Outperform → Neutral $41 → $37
Jul-27-18Upgrade Barrington Research Mkt Perform → Outperform $48
Jun-20-18Downgrade First Analysis Sec Overweight → Equal-Weight $45 → $34
Jun-20-18Downgrade Barrington Research Outperform → Mkt Perform
May-04-18Upgrade Barrington Research Mkt Perform → Outperform $39
Feb-23-18Downgrade Barrington Research Outperform → Mkt Perform
Jan-24-18Upgrade First Analysis Sec Equal-Weight → Overweight $45 → $68
Oct-27-17Reiterated Barrington Research Outperform $53 → $57
May-09-16Upgrade Singular Research BUY - Long-Term → Buy $60
Dec-10-21 05:00PM  
Nov-18-21 04:01PM  
Nov-13-21 06:24AM  
Nov-05-21 03:30PM  
Nov-04-21 06:35PM  
Nov-01-21 09:00AM  
Oct-28-21 03:06PM  
Oct-18-21 09:00AM  
Sep-30-21 09:00AM  
Sep-14-21 09:00AM  
Sep-07-21 10:00AM  
Sep-01-21 10:05AM  
Aug-15-21 03:03AM  
Aug-06-21 08:01AM  
Aug-05-21 04:05PM  
Jul-19-21 10:00AM  
Jul-01-21 09:00AM  
Jun-04-21 01:42AM  
Jun-03-21 08:00AM  
May-13-21 11:00AM  
May-07-21 04:31AM  
May-06-21 08:05PM  
May-04-21 10:30AM  
Apr-15-21 05:15PM  
Apr-05-21 09:25AM  
Mar-30-21 11:28AM  
Mar-23-21 07:30PM  
Mar-11-21 12:15PM  
Mar-09-21 09:02AM  
Mar-06-21 01:21AM  
Mar-04-21 10:30PM  
Feb-28-21 01:47AM  
Feb-09-21 03:00PM  
Jan-04-21 08:22AM  
Dec-30-20 12:03AM  
Dec-21-20 08:46AM  
Dec-16-20 06:47PM  
Nov-09-20 08:46AM  
Nov-04-20 09:32PM  
Oct-31-20 08:25AM  
Oct-28-20 12:32PM  
Oct-22-20 04:05PM  
Oct-21-20 04:05PM  
Oct-15-20 12:31PM  
Sep-24-20 11:40AM  
Sep-08-20 04:53PM  
Sep-07-20 11:40AM  
Sep-03-20 02:34PM  
Aug-21-20 11:40AM  
Aug-10-20 07:55AM  
Aug-05-20 04:09PM  
Aug-04-20 11:00AM  
Jul-30-20 07:30PM  
Jul-23-20 12:32PM  
Jul-20-20 07:00AM  
Jul-16-20 04:05PM  
Jul-15-20 12:31PM  
Jun-23-20 11:50AM  
Jun-02-20 04:05PM  
May-12-20 04:05PM  
May-08-20 11:00PM  
May-07-20 04:05PM  
May-01-20 06:34AM  
Apr-28-20 11:40AM  
Apr-27-20 08:30AM  
Apr-23-20 04:05PM  
Apr-08-20 04:05PM  
Apr-02-20 12:45PM  
Mar-26-20 06:12AM  
Mar-11-20 07:51AM  
Mar-04-20 08:30AM  
Feb-27-20 07:52AM  
Feb-21-20 07:46AM  
Feb-20-20 07:15PM  
Feb-13-20 12:31PM  
Feb-12-20 04:05PM  
Feb-06-20 05:14PM  
Feb-04-20 05:38AM  
Feb-03-20 04:30PM  
Jan-29-20 04:30PM  
Jan-24-20 04:05PM  
Jan-13-20 03:00PM  
Jan-08-20 11:47AM  
Jan-06-20 08:30AM  
Dec-30-19 08:22AM  
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levitz Michael LEVP, CFO, TreasurerAug 12Buy40.2077731,2397,486Aug 13 12:30 PM
Levitz Michael LEVP, CFO, TreasurerAug 11Buy40.212,850114,5876,709Aug 13 12:30 PM
Levitz Michael LEVP, CFO, TreasurerAug 10Option Exercise0.003,85903,859Aug 12 04:31 PM
Loerop JamesEVP Business DevelopmentJul 08Option Exercise0.003,00006,323Jul 12 04:15 PM
Blanchard Cheryl RPresident, CEO, DirectorJun 15Option Exercise33.402,994100,00037,472Jun 17 04:31 PM
HENNEMAN JOHN B IIIDirectorMay 18Buy42.862,00085,72011,310May 20 04:39 PM
LAND RAYMOND JDirectorMay 12Sale42.602,00085,2007,953May 14 04:31 PM
Blanchard Cheryl RPresident, CEO, DirectorApr 26Option Exercise0.0024,575034,478Apr 28 05:00 PM
Colleran DavidEVP, General Counsel, Corp SecMar 04Option Exercise0.002,50002,500Mar 08 05:06 PM
Finnerty ThomasEVP Human ResourcesFeb 26Option Exercise0.003,000012,582Mar 01 05:18 PM
Loerop JamesEVP Business DevelopmentFeb 25Option Exercise0.001,56703,323Mar 01 05:19 PM
Finnerty ThomasEVP Human ResourcesFeb 25Option Exercise0.002,833010,414Mar 01 05:18 PM